REHOVOT, Israel and HOBOKEN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products ...
TEL AVIV, July 2 (Reuters) - Kamada has won U.S. approval for its treatment of a lung-damaging condition, Alpha-1 Antitrypsin deficiency (AATD), and hopes to win 10 percent of the U.S. market, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results